📊 ADGM Key Takeaways
Is Adagio Medical Holdings, Inc. (ADGM) a Good Investment?
Adagio Medical is in severe financial distress with zero revenue, negative stockholders' equity of -$1.3M, and substantial operating losses of -$17.8M. The company is burning cash at an unsustainable rate with negative free cash flow of -$15.7M, while carrying $21.2M in long-term debt against only $4.7M in cash, indicating imminent liquidity crisis.
Adagio Medical Holdings appears fundamentally very weak based on the latest SEC data: it generated no revenue while posting a $21.78M net loss and burning $15.74M of free cash flow. The balance sheet is stressed, with negative equity, sub-1.0 liquidity ratios, and only $4.67M of cash against ongoing operating losses, which points to high financing and execution risk.
Why Buy Adagio Medical Holdings, Inc. Stock? ADGM Key Strengths
- Maintains $4.7M cash position providing short-term runway
- Medical device sector has growth potential if company survives
- Recent insider activity suggests management engagement despite challenges
- Total assets of $31.55M provide some operating base to support development and commercialization efforts
- Capital expenditure is relatively modest at $865K, so cash usage is not being driven by heavy fixed-asset expansion
- Recent SEC data as of 2025-09-30 gives timely visibility into the company's financial position
ADGM Stock Risks: Adagio Medical Holdings, Inc. Investment Risks
- Zero revenue indicates complete failure to commercialize products or generate market acceptance
- Negative stockholders' equity of -$1.3M represents technical insolvency
- Negative free cash flow of -$15.7M with only $4.7M cash means 3-4 months of runway at current burn rate
- Current ratio of 0.84x and quick ratio of 0.68x indicate inability to meet short-term obligations
- $21.2M long-term debt burden with no revenue stream to service debt
- ROA of -69% demonstrates severe asset inefficiency and value destruction
- Zero revenue indicates the business has not yet demonstrated commercial traction or operating leverage
- Negative stockholders' equity and current ratio of 0.84x signal a fragile financial position
- Free cash flow burn of $15.74M versus $4.67M in cash implies limited runway without additional capital
Key Metrics to Watch
- Cash burn rate and months of runway remaining
- Progress toward revenue generation or product commercialization
- Debt restructuring or refinancing activities
- Changes in stockholders' equity trajectory
- Operating expense reduction initiatives
- Quarterly revenue generation and commercialization progress
- Cash balance relative to operating cash burn
Adagio Medical Holdings, Inc. (ADGM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ADGM Profit Margin, ROE & Profitability Analysis
ADGM vs Healthcare Sector: How Adagio Medical Holdings, Inc. Compares
How Adagio Medical Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Adagio Medical Holdings, Inc. Stock Overvalued? ADGM Valuation Analysis 2026
Based on fundamental analysis, Adagio Medical Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Adagio Medical Holdings, Inc. Balance Sheet: ADGM Debt, Cash & Liquidity
ADGM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Adagio Medical Holdings, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-26.08 indicates the company is currently unprofitable.
ADGM Revenue Growth, EPS Growth & YoY Performance
ADGM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | $3.6M | $0.02 |
| Q2 2025 | $254.0K | -$3.9M | $-0.35 |
| Q1 2025 | $26.0K | -$7.7M | $-0.51 |
| Q3 2024 | $41.0K | $3.6M | $0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Adagio Medical Holdings, Inc. Dividends, Buybacks & Capital Allocation
ADGM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Adagio Medical Holdings, Inc. (CIK: 0002006986)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ADGM
What is the AI rating for ADGM?
Adagio Medical Holdings, Inc. (ADGM) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ADGM's key strengths?
Claude: Maintains $4.7M cash position providing short-term runway. Medical device sector has growth potential if company survives. ChatGPT: Total assets of $31.55M provide some operating base to support development and commercialization efforts. Capital expenditure is relatively modest at $865K, so cash usage is not being driven by heavy fixed-asset expansion.
What are the risks of investing in ADGM?
Claude: Zero revenue indicates complete failure to commercialize products or generate market acceptance. Negative stockholders' equity of -$1.3M represents technical insolvency. ChatGPT: Zero revenue indicates the business has not yet demonstrated commercial traction or operating leverage. Negative stockholders' equity and current ratio of 0.84x signal a fragile financial position.
What is ADGM's revenue and growth?
Adagio Medical Holdings, Inc. reported revenue of $0.0.
Does ADGM pay dividends?
Adagio Medical Holdings, Inc. does not currently pay dividends.
Where can I find ADGM SEC filings?
Official SEC filings for Adagio Medical Holdings, Inc. (CIK: 0002006986) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ADGM's EPS?
Adagio Medical Holdings, Inc. has a diluted EPS of $-1.42.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ADGM a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Adagio Medical Holdings, Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ADGM stock overvalued or undervalued?
Valuation metrics for ADGM: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ADGM stock in 2026?
Our dual AI analysis gives Adagio Medical Holdings, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ADGM's free cash flow?
Adagio Medical Holdings, Inc.'s operating cash flow is $-14.9M, with capital expenditures of $865.0K.
How does ADGM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.84 (avg: 2).